Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
After finishing at $79.98 in the prior trading day, Ionis Pharmaceuticals Inc (NASDAQ: IONS) closed at $78.97, down -1.26%. In other words, the price has decreased by -$1.26 from its previous closing price. On the day, 1.14 million shares were traded. IONS stock price reached its highest trading level at $79.99 during the session, while it also had its lowest trading level at $78.555.
Ratios:
Our goal is to gain a better understanding of IONS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.78 and its Current Ratio is at 2.79. In the meantime, Its Debt-to-Equity ratio is 3.32 whereas as Long-Term Debt/Eq ratio is at 2.27.
On September 26, 2025, Goldman Upgraded its rating to Neutral which previously was Sell but kept the price unchanged to $65.
BMO Capital Markets Upgraded its Market Perform to Outperform on September 03, 2025, while the target price for the stock was maintained at $70.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 01 ’25 when WENDER JOSEPH H sold 28,000 shares for $80.82 per share. The transaction valued at 2,262,848 led to the insider holds 36,035 shares of the business.
Joseph Wender bought 14,479 shares of IONS for $1,187,133 on Dec 01 ’25. On Nov 25 ’25, another insider, KLEIN JOSEPH III, who serves as the Director of the company, sold 12,000 shares for $80.00 each. As a result, the insider received 960,000 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IONS now has a Market Capitalization of 12791118848 and an Enterprise Value of 12611216384. For the stock, the TTM Price-to-Sale (P/S) ratio is 13.22 while its Price-to-Book (P/B) ratio in mrq is 20.59. Its current Enterprise Value per Revenue stands at 13.042 whereas that against EBITDA is -47.269.
Stock Price History:
The Beta on a monthly basis for IONS is 0.28, which has changed by 1.3055634 over the last 52 weeks, in comparison to a change of 0.17673707 over the same period for the S&P500. Over the past 52 weeks, IONS has reached a high of $83.61, while it has fallen to a 52-week low of $23.95. The 50-Day Moving Average of the stock is 3.15%, while the 200-Day Moving Average is calculated to be 54.09%.
Shares Statistics:
The stock has traded on average 2.39M shares per day over the past 3-months and 1717730 shares per day over the last 10 days, according to various share statistics. A total of 161.14M shares are outstanding, with a floating share count of 158.82M. Insiders hold about 1.95% of the company’s shares, while institutions hold 103.62% stake in the company. Shares short for IONS as of 1765756800 were 16086183 with a Short Ratio of 6.74, compared to 1763078400 on 14223973. Therefore, it implies a Short% of Shares Outstanding of 16086183 and a Short% of Float of 13.11.
Earnings Estimates
The firm’s stock currently is rated by 6.0 analysts. The consensus estimate for the next quarter is -$0.5, with high estimates of -$0.34 and low estimates of -$0.65. Analysts are recommending an EPS of between -$1.2 and -$1.87 for the fiscal current year, implying an average EPS of -$1.65. EPS for the following year is -$2.31, with 9.0 analysts recommending between -$1.08 and -$3.39.
Revenue Estimates
14 analysts predict $153.14M in revenue for. The current quarter. It ranges from a high estimate of $176.1M to a low estimate of $124.5M. As of. The current estimate, Ionis Pharmaceuticals Inc’s year-ago sales were $227MFor the next quarter, 14 analysts are estimating revenue of $188.41M. There is a high estimate of $241.6M for the next quarter, whereas the lowest estimate is $145.53M.
A total of 20 analysts have provided revenue estimates for IONS’s current fiscal year. The highest revenue estimate was $922.7M, while the lowest revenue estimate was $865.1M, resulting in an average revenue estimate of $896.65M. In the same quarter a year ago, actual revenue was $705MBased on 20 analysts’ estimates, the company’s revenue will be $905.4M in the next fiscal year. The high estimate is $1.15B and the low estimate is $686.83M.
